In both in vitro and in vivo preclinical studies, targeting SETD2 with EZM0414 significantly reduced the growth of t(4; 14) multiple myeloma (MM), as well as non-t(4; 14) MM and DLBCL cell lines.142. This evidence concerns the gene SETD2 and Miyoshi myopathy.